Diary - News
All news Alizé Pharma raises 5 million
Alizé Pharma SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, today announces that it has closed a new financing round of EUR 5 million (USD 6.6 million).
The funds will be used to continue the clinical program for AZP-531, including the set-up and completion of two clinical trials: a Phase II trial in hyperphagia associated with Prader-Willi syndrome and a Phase Ib trial in type 2 diabetes.
